US5585362A
(en)
*
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
EP0673431A1
(de)
*
|
1992-12-03 |
1995-09-27 |
Genzyme Corporation |
GENTHERAPIE DER MYKOVISCIDOSES (kystic fibroses)
|
WO1994023582A1
(en)
*
|
1993-04-08 |
1994-10-27 |
Genetic Therapy, Inc. |
Adenoviral vectors including dna encoding lung surfactant protein
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
US6133028A
(en)
*
|
1993-05-28 |
2000-10-17 |
Transgene S.A. |
Defective adenoviruses and corresponding complementation lines
|
JPH08511423A
(ja)
*
|
1993-06-10 |
1996-12-03 |
ジェネティック セラピー,インコーポレイテッド |
血友病治療のためのアデノウイルスベクター
|
US20020136708A1
(en)
|
1993-06-24 |
2002-09-26 |
Graham Frank L. |
System for production of helper dependent adenovirus vectors based on use of endonucleases
|
CA2144040A1
(fr)
*
|
1993-07-13 |
1995-01-26 |
Michel Perricaudet |
Vecteurs adenoviraux defectifs et utilisation en therapie genique
|
US5631236A
(en)
|
1993-08-26 |
1997-05-20 |
Baylor College Of Medicine |
Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
|
US6057299A
(en)
*
|
1994-01-13 |
2000-05-02 |
Calydon, Inc. |
Tissue-specific enhancer active in prostate
|
US5698443A
(en)
*
|
1995-06-27 |
1997-12-16 |
Calydon, Inc. |
Tissue specific viral vectors
|
US5830686A
(en)
*
|
1994-01-13 |
1998-11-03 |
Calydon |
Tissue-specific enhancer active in prostate
|
EP0668350B2
(de)
*
|
1994-02-16 |
2008-12-03 |
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma
|
US7252989B1
(en)
*
|
1994-04-04 |
2007-08-07 |
Board Of Regents, The University Of Texas System |
Adenovirus supervector system
|
WO1995029993A1
(en)
*
|
1994-04-28 |
1995-11-09 |
The University Of Michigan |
Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
|
US6451571B1
(en)
|
1994-05-02 |
2002-09-17 |
University Of Washington |
Thymidine kinase mutants
|
US5851806A
(en)
*
|
1994-06-10 |
1998-12-22 |
Genvec, Inc. |
Complementary adenoviral systems and cell lines
|
ATE336587T1
(de)
*
|
1994-06-10 |
2006-09-15 |
Genvec Inc |
Adenoviren-vektor systeme und zelllinien
|
DK0707071T3
(da)
*
|
1994-08-16 |
2003-11-17 |
Crucell Holland Bv |
Rekombinante vektorer afledt fra adenovirus til anvendelse i genterapi
|
FR2725213B1
(fr)
*
|
1994-10-04 |
1996-11-08 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation en therapie genique
|
FR2725726B1
(fr)
*
|
1994-10-17 |
1997-01-03 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en therapie genique
|
DE69534166T2
(de)
*
|
1994-10-28 |
2006-03-09 |
Trustees Of The University Of Pennsylvania |
Rekombinanter adenovirus und methoden zu dessen verwendung
|
FR2726285B1
(fr)
*
|
1994-10-28 |
1996-11-29 |
Centre Nat Rech Scient |
Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
|
US5872005A
(en)
*
|
1994-11-03 |
1999-02-16 |
Cell Genesys Inc. |
Packaging cell lines for adeno-associated viral vectors
|
NZ300387A
(en)
*
|
1994-12-12 |
2001-07-27 |
Genetic Therapy Inc |
Adenoviral vector modified to reduce host immune and inflammatory responses and its use in gene therapy treatment
|
FR2729674B1
(fr)
*
|
1995-01-20 |
1997-04-11 |
Centre Nat Rech Scient |
Cellules pour la production d'adenovirus recombinants
|
FR2738575B1
(fr)
*
|
1995-09-08 |
1997-10-10 |
Centre Nat Rech Scient |
Cellules pour la production d'adenovirus recombinants
|
FR2741891B1
(fr)
*
|
1995-06-01 |
1998-01-09 |
Centre Nat Rech Scient |
Cellules pour la production d'adenovirus recombinants
|
IL116816A
(en)
*
|
1995-01-20 |
2003-05-29 |
Rhone Poulenc Rorer Sa |
Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
|
FR2730411B1
(fr)
*
|
1995-02-14 |
1997-03-28 |
Centre Nat Rech Scient |
Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
|
US6251957B1
(en)
|
1995-02-24 |
2001-06-26 |
Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
US6372208B1
(en)
|
1999-09-28 |
2002-04-16 |
The Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
FR2731710B1
(fr)
*
|
1995-03-14 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
|
JP3770333B2
(ja)
*
|
1995-03-15 |
2006-04-26 |
大日本住友製薬株式会社 |
組換えdnaウイルスおよびその製造方法
|
US5707618A
(en)
*
|
1995-03-24 |
1998-01-13 |
Genzyme Corporation |
Adenovirus vectors for gene therapy
|
FR2732357B1
(fr)
|
1995-03-31 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
|
WO1996033280A1
(en)
*
|
1995-04-17 |
1996-10-24 |
Board Of Regents, The University Of Texas System |
An adenovirus helper-virus system
|
US5756283A
(en)
*
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
US5698202A
(en)
*
|
1995-06-05 |
1997-12-16 |
The Wistar Institute Of Anatomy & Biology |
Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
AU6261696A
(en)
|
1995-06-05 |
1996-12-24 |
Trustees Of The University Of Pennsylvania, The |
A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
|
US5985846A
(en)
*
|
1995-06-07 |
1999-11-16 |
Baylor College Of Medicine |
Gene therapy for muscular dystrophy
|
SI0833934T2
(sl)
*
|
1995-06-15 |
2013-04-30 |
Crucell Holland B.V. |
Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
|
US6265212B1
(en)
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
FR2735789B1
(fr)
*
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
US6676935B2
(en)
|
1995-06-27 |
2004-01-13 |
Cell Genesys, Inc. |
Tissue specific adenoviral vectors
|
WO1997003635A2
(en)
|
1995-07-17 |
1997-02-06 |
Board Of Regents, The University Of Texas System |
p16 EXPRESSION CONSTRUCTS AND THEIR APPLICATION IN CANCER THERAPY
|
US7163925B1
(en)
|
1995-07-17 |
2007-01-16 |
Board Of Regents, The University Of Texas System |
p16 expression constructs and their application in cancer therapy
|
FR2737221B1
(fr)
*
|
1995-07-24 |
1997-10-17 |
Transgene Sa |
Nouveaux vecteurs viraux pour la therapie genique
|
FR2737222B1
(fr)
*
|
1995-07-24 |
1997-10-17 |
Transgene Sa |
Nouveaux vecteurs viraux et lignee pour la therapie genique
|
EP0840797B1
(de)
*
|
1995-07-25 |
2014-09-03 |
Crucell Holland B.V. |
Verfahren und mittel zur gezielten freisetzung von genen
|
US5837511A
(en)
*
|
1995-10-02 |
1998-11-17 |
Cornell Research Foundation, Inc. |
Non-group C adenoviral vectors
|
JP2006075171A
(ja)
*
|
1995-11-09 |
2006-03-23 |
Avigen Inc |
組換えaavビリオン産生における使用のための補助機能
|
US6004797A
(en)
*
|
1995-11-09 |
1999-12-21 |
Avigen, Inc. |
Adenovirus helper-free recombinant AAV Virion production
|
US5891690A
(en)
*
|
1996-04-26 |
1999-04-06 |
Massie; Bernard |
Adenovirus E1-complementing cell lines
|
WO1997045550A2
(en)
*
|
1996-05-31 |
1997-12-04 |
Baxter International Inc. |
Mini-adenoviral vector
|
FR2750433B1
(fr)
*
|
1996-07-01 |
1998-08-14 |
Rhone Poulenc Rorer Sa |
Procede de production d'adenovirus recombinants
|
US6485958B2
(en)
*
|
1996-07-01 |
2002-11-26 |
Gencell Sa |
Method for producing recombinant adenovirus
|
US20040156861A1
(en)
*
|
1996-07-11 |
2004-08-12 |
Figdor Carl Gustav |
Melanoma associated peptide analogues and vaccines against melanoma
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US7008776B1
(en)
*
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
IL129986A0
(en)
|
1996-12-06 |
2000-02-29 |
Rhone Poulenc Rorer Pharma |
Polypeptides encoded by a human lipase-like gene compositions and methods
|
US6403370B1
(en)
|
1997-02-10 |
2002-06-11 |
Genstar Therapeutics Corporation |
Oncolytic/immunogenic complementary-adenoviral vector system
|
WO1998037185A2
(en)
*
|
1997-02-20 |
1998-08-27 |
The Board Of Regents Of The University Of Texas System |
Vectors for controlled gene expression
|
FR2761689B1
(fr)
|
1997-04-02 |
1999-06-25 |
Transgene Sa |
Fibre adenovirale modifiee et adenovirus cibles
|
WO1998049321A2
(en)
|
1997-04-28 |
1998-11-05 |
Rhone-Poulenc Rorer S.A. |
Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
|
US5849561A
(en)
*
|
1997-05-22 |
1998-12-15 |
Cornell Research Foundation, Inc. |
Method for the production of non-group C adenoviral vectors
|
WO1998054345A1
(en)
*
|
1997-05-30 |
1998-12-03 |
Baxter International Inc. |
Mini-adenoviral vector
|
FR2766091A1
(fr)
|
1997-07-18 |
1999-01-22 |
Transgene Sa |
Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
US6653088B1
(en)
|
1997-10-24 |
2003-11-25 |
Aventis Pharma S.A. |
Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide
|
CA2307016A1
(en)
*
|
1997-10-24 |
1999-05-06 |
Life Technologies, Inc. |
Recombinational cloning using nucleic acids having recombination sites
|
ATE476508T1
(de)
|
1997-11-06 |
2010-08-15 |
Novartis Vaccines & Diagnostic |
Neisseriale antigene
|
JP2002500039A
(ja)
|
1998-01-08 |
2002-01-08 |
アベンティス ファーマスーティカルズ プロダクツ インコーポレイテッド |
機能あるヒトリポタンパク質(a)を発現するトランスジェニックウサギ
|
EP2210945B1
(de)
|
1998-01-14 |
2013-06-26 |
Novartis Vaccines and Diagnostics S.r.l. |
Antigene aus Neisseria meningitidis
|
EP1053317B1
(de)
|
1998-02-13 |
2006-11-02 |
Köster, Hubert |
Verwendung von ribozymen zur bestimmung der funktion von genen
|
US5981225A
(en)
*
|
1998-04-16 |
1999-11-09 |
Baylor College Of Medicine |
Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
|
US6670188B1
(en)
|
1998-04-24 |
2003-12-30 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
NZ508366A
(en)
|
1998-05-01 |
2004-03-26 |
Chiron Corp |
Neisseria meningitidis antigens and compositions
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
US6413776B1
(en)
|
1998-06-12 |
2002-07-02 |
Galapagos Geonomics N.V. |
High throughput screening of gene function using adenoviral libraries for functional genomics applications
|
JP2002528056A
(ja)
|
1998-08-28 |
2002-09-03 |
デューク・ユニバーシティー |
IVa2、100K及び/又は末端前タンパク質配列における欠失型アデノウイルス
|
US6225113B1
(en)
|
1998-12-04 |
2001-05-01 |
Genvec, Inc. |
Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
|
DE19856065A1
(de)
*
|
1998-12-04 |
2000-06-15 |
Centeon Pharma Gmbh |
Rekombinanter, adenoviraler Vektor mit limitierter Autoreplikationsfähigkeit in vivo
|
FR2787465A1
(fr)
|
1998-12-21 |
2000-06-23 |
Transgene Sa |
Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
|
US6441156B1
(en)
*
|
1998-12-30 |
2002-08-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Calcium channel compositions and methods of use thereof
|
EP1016726A1
(de)
*
|
1998-12-30 |
2000-07-05 |
Introgene B.V. |
Gentherapie zur Förderung der Angiogenesis
|
AU769735B2
(en)
*
|
1999-02-18 |
2004-02-05 |
Advec, Inc. |
A system for production of helper dependent adenovirus vectors based on use of endonucleases
|
ES2162551B1
(es)
*
|
1999-04-09 |
2002-07-01 |
Univ Madrid Autonoma |
Procedimiento para la replicacion selectiva de adenovirus defectivos en celulas tumorales.
|
US6490775B1
(en)
*
|
1999-04-23 |
2002-12-10 |
Veri-Tek Inc. |
Press operation verification system
|
US7368261B1
(en)
|
1999-04-30 |
2008-05-06 |
Novartis Vaccines And Diagnostics Srl |
Conserved Neisserial antigens
|
US7226786B2
(en)
|
1999-05-18 |
2007-06-05 |
Dnavec Research Inc. |
Envelope gene-deficient Paramyxovirus vector
|
US20030166252A1
(en)
*
|
1999-05-18 |
2003-09-04 |
Kaio Kitazato |
Paramyxovirus-derived RNP
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
FR2794771B1
(fr)
*
|
1999-06-11 |
2001-08-10 |
Aventis Pharma Sa |
Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
|
CA2378539A1
(en)
*
|
1999-07-06 |
2001-01-11 |
Merck & Co., Inc. |
Adenovirus carrying gag gene hiv vaccine
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
FR2799472B1
(fr)
*
|
1999-10-07 |
2004-07-16 |
Aventis Pharma Sa |
Preparation d'adenovirus recombinants et de banques adenovirales
|
MXPA02004283A
(es)
|
1999-10-29 |
2002-10-17 |
Chiron Spa |
Peptidos antigenicos neisseriales.
|
CN1254719A
(zh)
*
|
1999-11-19 |
2000-05-31 |
钱其军 |
一种缺陷型腺病毒及其构建方法
|
US6558948B1
(en)
|
1999-11-23 |
2003-05-06 |
Stefan Kochanek |
Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
|
DK1248647T3
(da)
|
2000-01-17 |
2010-09-27 |
Novartis Vaccines & Diagnostic |
Ydre membranvesikel (OMV) vaccine omfattende N. meningitidis serogruppe B ydre membranproteiner
|
MXPA02009481A
(es)
|
2000-03-31 |
2004-05-14 |
Aventis Pharma Inc |
Factor inductor del factor nuclear kb.
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
US20040204379A1
(en)
*
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
EP1167533A1
(de)
*
|
2000-06-23 |
2002-01-02 |
Vereniging Voor Christelijk Wetenschappelijk Onderwijs |
Verfahren und Mittel zur Komplementation von viraler Proteinexpression in stabilen Zelllinien
|
US7198924B2
(en)
|
2000-12-11 |
2007-04-03 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
US6733993B2
(en)
*
|
2000-09-15 |
2004-05-11 |
Merck & Co., Inc. |
Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
|
CA2422882A1
(en)
*
|
2000-09-15 |
2002-03-21 |
Merck & Co., Inc. |
Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
|
US20040101957A1
(en)
*
|
2001-09-14 |
2004-05-27 |
Emini Emilio A. |
Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
|
US6916635B2
(en)
*
|
2000-10-02 |
2005-07-12 |
The Research Foundation Of State University Of New York |
Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
|
MXPA03003690A
(es)
|
2000-10-27 |
2004-05-05 |
Chiron Spa |
Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
|
US7060442B2
(en)
|
2000-10-30 |
2006-06-13 |
Regents Of The University Of Michigan |
Modulators on Nod2 signaling
|
JP2002142770A
(ja)
*
|
2000-11-08 |
2002-05-21 |
Dnavec Research Inc |
循環系への遺伝子送達用パラミクソウイルスベクター
|
AU2002227450B2
(en)
|
2000-12-28 |
2008-02-28 |
Wyeth |
Recombinant protective protein from $I(streptococcus pneumoniae)
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
AUPR518501A0
(en)
|
2001-05-22 |
2001-06-14 |
Unisearch Limited |
Yin yang-1
|
US6677156B2
(en)
|
2001-07-23 |
2004-01-13 |
Genvec, Inc. |
Non-adenoviral gene product-based complementing cells for adenoviral vectors
|
US6682929B2
(en)
|
2001-07-23 |
2004-01-27 |
Genvec, Inc. |
Adenovector complementing cells
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
NZ562929A
(en)
|
2001-12-12 |
2009-07-31 |
Novartis Vaccines & Diagnostic |
Immunisation against chlamydia trachomatis
|
US20030158112A1
(en)
|
2002-02-15 |
2003-08-21 |
Johns Hopkins University School Of Medicine |
Selective induction of apoptosis to treat ocular disease
|
CA2478508C
(en)
*
|
2002-04-25 |
2013-07-02 |
Crucell Holland B.V. |
Stable adenoviral vectors and methods for propagation thereof
|
CA2484287A1
(en)
*
|
2002-04-30 |
2003-11-13 |
Dnavec Research Inc. |
Pharmaceutical- or gene-carrier compositions with reduced hemagglutinating activity
|
NZ571508A
(en)
|
2002-05-24 |
2010-05-28 |
Schering Corp |
Neutralizing human anti-IGFR antibody
|
WO2004009768A2
(en)
*
|
2002-07-18 |
2004-01-29 |
Invitrogen Corporation |
Viral vectors containing recombination sites
|
CA2421269A1
(en)
|
2002-08-09 |
2004-02-09 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
US7977049B2
(en)
|
2002-08-09 |
2011-07-12 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US20040052161A1
(en)
*
|
2002-09-17 |
2004-03-18 |
Steven Liao |
Mechanical clock having wireless manipulation and adjustment function
|
JPWO2004038029A1
(ja)
*
|
2002-10-24 |
2006-02-23 |
株式会社ディナベック研究所 |
T細胞に遺伝子を導入する方法
|
CN1756845A
(zh)
|
2002-11-12 |
2006-04-05 |
A·B·德塞罗斯 |
腺病毒载体疫苗
|
US20040225077A1
(en)
|
2002-12-30 |
2004-11-11 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
EP1642966B1
(de)
*
|
2003-06-30 |
2010-03-03 |
Dnavec Research Inc. |
Negativ-strang rna-virus-vektoren, welche ein gen mit veränderten hypermutierbaren regionen tragen
|
US7960148B2
(en)
*
|
2003-07-02 |
2011-06-14 |
Verenium Corporation |
Glucanases, nucleic acids encoding them and methods for making and using them
|
US7026164B2
(en)
*
|
2003-07-03 |
2006-04-11 |
Cell Genesys, Inc. |
Adenovirus packaging cell lines
|
ES2359473T3
(es)
|
2003-07-21 |
2011-05-23 |
Transgene S.A. |
Citoquinas multifuncionales.
|
KR101062140B1
(ko)
|
2003-07-21 |
2011-09-05 |
트랜스진 에스.에이. |
향상된 시토신 디아미네이즈 활성을 갖는 폴리펩티드
|
EP1687334B1
(de)
|
2003-11-24 |
2014-01-08 |
MicroVAX, LLC |
Mucinantigenimpfstoff
|
ATE469984T1
(de)
*
|
2003-12-01 |
2010-06-15 |
Life Technologies Corp |
Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
|
US8828957B2
(en)
*
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
WO2005058369A2
(en)
*
|
2003-12-15 |
2005-06-30 |
The University Of Iowa Research Foundation |
Compositions of l-caldesmon for treating viral infection
|
CN1934257A
(zh)
*
|
2004-01-22 |
2007-03-21 |
株式会社载体研究所 |
病毒载体的制备方法
|
US7432057B2
(en)
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
DK1780269T3
(da)
*
|
2004-02-23 |
2009-10-12 |
Crucell Holland Bv |
Virusrensningsmetoder
|
US8268324B2
(en)
|
2004-03-29 |
2012-09-18 |
Galpharma Co., Ltd. |
Modified galectin 9 proteins and use thereof
|
EP1737885A2
(de)
|
2004-04-12 |
2007-01-03 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Verwendung von adenoviralen vektoren zur erzeugung einer immunantwort
|
US7604798B2
(en)
|
2004-07-15 |
2009-10-20 |
Northwestern University |
Methods and compositions for importing nucleic acids into cell nuclei
|
JP4772045B2
(ja)
|
2004-07-16 |
2011-09-14 |
アメリカ合衆国 |
Cmv/r核酸コンストラクトを含むaidsに対するワクチン
|
WO2006013564A2
(en)
*
|
2004-08-04 |
2006-02-09 |
S.A.E. Afikim Computerized Dairy Management Systems |
A method and a system for locating objects in a defined area
|
CN101535492A
(zh)
|
2005-02-11 |
2009-09-16 |
南加州大学 |
表达含有二硫键的蛋白质的方法
|
DE602006003420D1
(de)
*
|
2005-04-11 |
2008-12-11 |
Crucell Holland Bv |
Virusreinigung mit ultrafiltration
|
KR20130114758A
(ko)
|
2005-05-27 |
2013-10-17 |
오스페달레 산 라파엘 에스.알.엘. |
Mi-rna를 포함하는 유전자 벡터
|
WO2006130525A2
(en)
*
|
2005-05-31 |
2006-12-07 |
Sidney Kimmel Cancer Center |
Methods for immunotherapy of cancer
|
CA2620495A1
(en)
|
2005-08-31 |
2007-03-08 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
WO2007030588A1
(en)
*
|
2005-09-07 |
2007-03-15 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of replicators to prevent gene silencing
|
US20090162320A1
(en)
|
2005-10-28 |
2009-06-25 |
Dnavec Corporation |
Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus or dna virus spike protein
|
JP2009514536A
(ja)
*
|
2005-11-07 |
2009-04-09 |
シドニー キンメル キャンサー センター |
Cd40リガンド融合蛋白質ワクチン
|
WO2007059461A2
(en)
|
2005-11-10 |
2007-05-24 |
Genvec, Inc. |
Adenoviral vector-based foot-and-mouth disease vaccine
|
WO2007130501A2
(en)
*
|
2006-05-01 |
2007-11-15 |
University Of Southern California |
Combination therapy for treatment of cancer
|
EP2054431B1
(de)
|
2006-06-09 |
2011-08-31 |
Novartis AG |
Bakterielle adhäsine konformere
|
US8329669B2
(en)
|
2006-07-28 |
2012-12-11 |
Sanofi |
Composition and method for treatment of tumors
|
AU2007319604B2
(en)
|
2006-10-19 |
2011-03-24 |
Csl Limited |
High affinity antibody antagonists of interleukin-13 receptor alpha 1
|
WO2008060814A2
(en)
|
2006-10-19 |
2008-05-22 |
Merck & Co., Inc. |
ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
EP2390340A3
(de)
|
2007-01-30 |
2012-02-22 |
Transgene SA |
Papillomavirus E1 und E2-Polypeptiden mit reduziertem Identitätsanteil kodierender Vektor
|
US8470977B2
(en)
|
2008-03-14 |
2013-06-25 |
Transgene S.A. |
Antibody against the CSF-1R
|
ES2337973B8
(es)
|
2008-05-16 |
2011-07-21 |
Proyecto De Biomedicina Cima, S.L. |
Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
|
KR101504392B1
(ko)
*
|
2008-11-03 |
2015-03-19 |
크루셀 홀란드 비.브이. |
아데노바이러스 벡터의 제조방법
|
EP2356135B1
(de)
|
2008-11-05 |
2017-10-25 |
Wyeth LLC |
Immunogene multikomponentenzusammensetzung zur prävention einer erkrankung mit beta-hämolytischen streptokokken (bhs)
|
WO2010056901A2
(en)
|
2008-11-13 |
2010-05-20 |
University Of Southern California |
Method of expressing proteins with disulfide bridges with enhanced yields and activity
|
AU2010205717A1
(en)
|
2009-01-13 |
2010-07-22 |
Transgene Sa |
Use of a Saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
|
PL2382474T3
(pl)
|
2009-01-20 |
2015-08-31 |
Transgene Sa |
Rozpuszczalny ICAM-1 jako biomarker do prognozowania odpowiedzi terapeutycznej
|
WO2010096561A1
(en)
|
2009-02-18 |
2010-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic hiv/siv gag proteins and uses thereof
|
KR20110138354A
(ko)
|
2009-03-24 |
2011-12-27 |
트랜스진 에스.에이. |
환자를 모니터링하기 위한 바이오마커
|
SG175060A1
(en)
|
2009-04-17 |
2011-11-28 |
Transgene Sa |
Biomarker for monitoring patients
|
HUE028240T2
(en)
|
2009-07-10 |
2016-12-28 |
Transgene Sa |
Biomarker Patient Selection and Related Procedures
|
KR20120052352A
(ko)
|
2009-08-07 |
2012-05-23 |
트랜스진 에스.에이. |
Hbv 감염을 치료하는 조성물
|
EP2488635B1
(de)
|
2009-10-15 |
2013-11-20 |
Crucell Holland B.V. |
Verfahren zur Adenovirus-Reinigung aus Kulturen mit hoher Zelldichte
|
CN102791852B
(zh)
|
2009-10-15 |
2014-05-07 |
克鲁塞尔荷兰公司 |
纯化腺病毒颗粒的方法
|
US20120219583A1
(en)
|
2009-10-16 |
2012-08-30 |
Los Alamos National Security, Llc |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
WO2011057254A2
(en)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Simian adenoviral vector-based vaccines
|
WO2011057248A2
(en)
|
2009-11-09 |
2011-05-12 |
Genvec, Inc. |
Simian adenovirus and methods of use
|
AU2011214262B2
(en)
|
2010-02-15 |
2015-05-21 |
Crucell Holland B.V. |
Method for the production of Ad26 adenoviral vectors
|
EP2547362B1
(de)
|
2010-03-17 |
2021-08-25 |
Cornell University |
Unterbrochener impfstoff auf adenovirusbasis gegen drogenmissbrauch
|
WO2012021730A2
(en)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Respiratory syncytial virus (rsv) vaccine
|
HUE052850T2
(hu)
|
2010-08-23 |
2021-05-28 |
Wyeth Llc |
Neisseria meningitidis RLP2086 antigéneket tartalmazó stabil készítmények
|
NZ607224A
(en)
|
2010-09-10 |
2014-11-28 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
WO2012038367A1
(en)
|
2010-09-20 |
2012-03-29 |
Crucell Holland B.V. |
Therapeutic vaccination against active tuberculosis
|
BR112013004582A2
(pt)
|
2010-09-27 |
2016-09-06 |
Crucell Holland Bv |
método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
EP2654786B1
(de)
|
2010-12-20 |
2019-02-20 |
GenVec, Inc. |
Auf adenovirusvektor basierender impfstoff gegen denguefieber
|
US8911975B2
(en)
|
2011-02-08 |
2014-12-16 |
Mie University |
Method for producing virus vector for gene transfer
|
JPWO2012147370A1
(ja)
*
|
2011-04-28 |
2014-07-28 |
国立大学法人山口大学 |
ターミネータ配列を含む高発現用リバースプライマー及びリニアdna
|
WO2012162428A1
(en)
|
2011-05-23 |
2012-11-29 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Prime-boost vaccination for viral infection
|
TWI623618B
(zh)
|
2011-07-12 |
2018-05-11 |
傳斯堅公司 |
Hbv聚合酶突變體
|
WO2013045658A1
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
TW201321016A
(zh)
|
2011-09-29 |
2013-06-01 |
Transgene Sa |
免疫療法組成物及用於治療c型肝炎病毒感染之療程(二)
|
EP2764011B1
(de)
|
2011-10-05 |
2021-04-07 |
GenVec, Inc. |
Auf adenovirenvektoren-basierender impfstoff gegen das respiratorische synzytialvirus (rsv)
|
CN107937440A
(zh)
|
2011-10-05 |
2018-04-20 |
金维克有限公司 |
猴腺病毒(大猩猩)或腺病毒载体及其使用方法
|
JP6757119B2
(ja)
|
2011-10-05 |
2020-09-16 |
ジェンヴェック エルエルシー |
アーフェンアデノウイルス(ゴリラ)又はアデノウイルスベクター、及び使用方法
|
BR112014008284A2
(pt)
|
2011-10-05 |
2020-10-27 |
Genvec Inc. |
adenovirus (gorilla) simian ou vetores adenovirais e métodos de uso
|
US20130122038A1
(en)
|
2011-11-14 |
2013-05-16 |
The United States Of America As Represented By The Secretary Of The Department |
Heterologous prime-boost immunization using measles virus-based vaccines
|
EP2809346A1
(de)
|
2012-02-02 |
2014-12-10 |
GenVec, Inc. |
Auf adenoviralen vektoren basierender malaria-impfstoff
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
KR101763625B1
(ko)
|
2012-03-09 |
2017-08-01 |
화이자 인코포레이티드 |
수막염균 조성물 및 이의 사용 방법
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
DK2825640T3
(en)
|
2012-03-12 |
2016-08-01 |
Crucell Holland Bv |
BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
|
AP2014007993A0
(en)
|
2012-03-22 |
2014-10-31 |
Crucell Holland Bv |
Vaccine against RSV
|
US9125870B2
(en)
|
2012-03-22 |
2015-09-08 |
Crucell Holland B.V. |
Vaccine against RSV
|
WO2013180967A1
(en)
|
2012-05-29 |
2013-12-05 |
Genvec, Inc. |
Herpes simplex virus vaccine
|
EP2855669B1
(de)
|
2012-05-29 |
2018-10-10 |
GenVec, Inc. |
Modifizierte serotyp-28-adenovirusvektoren
|
WO2014009433A1
(en)
|
2012-07-10 |
2014-01-16 |
Transgene Sa |
Mycobacterium resuscitation promoting factor for use as adjuvant
|
KR20150058152A
(ko)
|
2012-07-10 |
2015-05-28 |
트랜스진 에스아이 |
마이코박테리아 항원 백신
|
EP2912069B1
(de)
|
2012-10-23 |
2019-07-31 |
Emory University |
Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
ES2685894T3
(es)
|
2013-03-08 |
2018-10-15 |
Pfizer Inc. |
Polipéptidos de fusión inmunogénicos
|
CA2940513C
(en)
|
2013-03-11 |
2023-08-15 |
University Of Florida Research Foundation, Inc. |
Delivery of card protein as therapy for ocular inflammation
|
CN105188745B
(zh)
|
2013-04-25 |
2019-10-18 |
扬森疫苗与预防公司 |
稳定化的可溶性融合前rsv f多肽
|
EP3010931B1
(de)
|
2013-06-17 |
2018-06-13 |
Janssen Vaccines & Prevention B.V. |
Stabilisierte lösliche präfusionierte rsv-f-polypeptide
|
RU2662968C2
(ru)
|
2013-09-08 |
2018-07-31 |
Пфайзер Инк. |
Иммуногенная композиция против neisseria meningitidis (варианты)
|
US9974737B2
(en)
|
2013-09-19 |
2018-05-22 |
Janssen Vaccines & Prevention B.V. |
Adenovirus formulations
|
EP3092000A1
(de)
|
2014-01-09 |
2016-11-16 |
Transgene SA |
Fusion von heterooligomeren mycobakteriellen antigenen
|
EP3107939B1
(de)
|
2014-02-19 |
2020-06-17 |
University of Florida Research Foundation, Inc. |
Abgabe einer nrf2-therapie zum schutz gegen reaktive sauerstoffspezies
|
US10400015B2
(en)
|
2014-09-04 |
2019-09-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant HIV-1 envelope proteins and their use
|
CA2965562C
(en)
|
2014-11-04 |
2023-11-21 |
Janssen Vaccines & Prevention B.V. |
Therapeutic hpv16 vaccines
|
US10420834B2
(en)
|
2014-12-24 |
2019-09-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant metapneumovirus F proteins and their use
|
CN107406835A
(zh)
|
2015-01-20 |
2017-11-28 |
美利坚合众国,由健康及人类服务部部长代表 |
表达嵌合rsv/bpiv3f蛋白的重组人/牛副流感病毒3(b/hpiv3)及其用途
|
EP3270959A1
(de)
|
2015-02-19 |
2018-01-24 |
Pfizer Inc |
Neisseria meningitidis-zusammensetzungen und verfahren dafür
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
KR20170140180A
(ko)
|
2015-02-24 |
2017-12-20 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
|
US20180052173A1
(en)
|
2015-03-18 |
2018-02-22 |
Janssen Vaccines & Prevention B.V. |
Assays for recombinant expression systems
|
WO2016164371A1
(en)
|
2015-04-07 |
2016-10-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Methods for inducing cell division of postmitotic cells
|
AU2016249798B2
(en)
|
2015-04-14 |
2022-05-26 |
Janssen Vaccines And Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
PL3319633T3
(pl)
|
2015-07-07 |
2021-04-19 |
Janssen Vaccines & Prevention B.V. |
Szczepionka przeciwko rsv
|
US10457708B2
(en)
|
2015-07-07 |
2019-10-29 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F polypeptides
|
BR112018003019A2
(pt)
|
2015-08-20 |
2018-09-25 |
Janssen Vaccines & Prevention Bv |
vacinas terapêuticas contra hpv18
|
EA036412B1
(ru)
|
2015-10-06 |
2020-11-09 |
Янссен Вэксинс Энд Превеншн Б.В. |
Способ обеспечения защиты аденовируса от разрушения, вызванного взаимодействием с пластиком, и применение 2-гидроксипропил--циклодекстрина для защиты аденовируса
|
WO2017139392A1
(en)
|
2016-02-08 |
2017-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant hiv-1 envelope proteins and their use
|
WO2017156272A1
(en)
|
2016-03-09 |
2017-09-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant hiv-1 envelope proteins and their use
|
WO2017174564A1
(en)
|
2016-04-05 |
2017-10-12 |
Janssen Vaccines & Prevention B.V. |
Vaccine against rsv
|
AU2017248021B2
(en)
|
2016-04-05 |
2021-08-12 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F proteins
|
EP3452087A1
(de)
|
2016-05-02 |
2019-03-13 |
Janssen Vaccines & Prevention B.V. |
Therapeutische hpv-impfstoffkombinationen
|
CA3023022A1
(en)
|
2016-05-04 |
2017-11-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
AU2017264562B2
(en)
|
2016-05-12 |
2023-03-09 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
JP2019523644A
(ja)
|
2016-05-30 |
2019-08-29 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
安定化された融合前rsv fタンパク質
|
EP3472327B1
(de)
|
2016-06-20 |
2020-08-19 |
Janssen Vaccines & Prevention B.V. |
Potenter und ausbalancierter bidirektionaler promotor
|
JP7229151B2
(ja)
|
2016-07-14 |
2023-02-27 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Hpvワクチン
|
US11155832B2
(en)
|
2016-09-30 |
2021-10-26 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into T cells
|
EP4070815A1
(de)
|
2016-10-03 |
2022-10-12 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Hiv-1-env-fusionspeptid-immunogene und deren verwendung
|
US20190328869A1
(en)
|
2016-10-10 |
2019-10-31 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
US10960070B2
(en)
|
2016-10-25 |
2021-03-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion coronavirus spike proteins and their use
|
EP3541420A2
(de)
|
2016-11-16 |
2019-09-25 |
Immunomic Therapeutics, Inc. |
Nukleinsäuren zur behandlung von allergien
|
WO2018109220A2
(en)
|
2016-12-16 |
2018-06-21 |
Institute For Research In Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof
|
SG11201906519RA
(en)
|
2017-01-31 |
2019-08-27 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
JP6721797B2
(ja)
|
2017-02-09 |
2020-07-15 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
異種遺伝子発現のための強力で短いプロモーター
|
WO2018176031A1
(en)
|
2017-03-24 |
2018-09-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Glycan-masked engineered outer domains of hiv-1 gp120 and their use
|
KR102637960B1
(ko)
|
2017-04-22 |
2024-02-21 |
이뮤노믹 쎄라퓨틱스, 인크. |
개선된 lamp 구축물
|
EP3618854A1
(de)
|
2017-05-02 |
2020-03-11 |
Immunomic Therapeutics, Inc. |
Lamp (lysosomale assoziierte membranprotein)-konstrukte mit krebsantigenen
|
CA3061278A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
WO2019053109A1
(en)
|
2017-09-15 |
2019-03-21 |
Janssen Vaccines & Prevention B.V. |
METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
|
JP2021502060A
(ja)
|
2017-10-16 |
2021-01-28 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
筋萎縮性側索硬化症(als)の治療
|
EP3697440A1
(de)
|
2017-10-16 |
2020-08-26 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Rekombinante hiv-1-hüllproteine und deren verwendung
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
KR20200074988A
(ko)
|
2017-10-31 |
2020-06-25 |
얀센 백신스 앤드 프리벤션 비.브이. |
아데노바이러스 벡터 및 이의 용도
|
BR112020007695A2
(pt)
|
2017-10-31 |
2020-10-20 |
Janssen Vaccines & Prevention B.V. |
adenovírus e seus usos
|
BR112020007698A2
(pt)
|
2017-10-31 |
2020-10-06 |
Janssen Vaccines & Prevention B.V. |
Sequência de ácido nucleico isolada, vetor, seu método de produção, célularecombinante, composição imunogênica, método para induzir uma resposta imune em um indivíduo, vacina e seu método de produção
|
KR20200074987A
(ko)
|
2017-10-31 |
2020-06-25 |
얀센 백신스 앤드 프리벤션 비.브이. |
아데노바이러스 및 이의 용도
|
BR112020014343A2
(pt)
|
2018-01-23 |
2020-12-08 |
Janssen Vaccines & Prevention B.V. |
Vacinas contra o vírus da influenza e seus usos
|
CA3092935A1
(en)
|
2018-03-06 |
2019-09-12 |
Precigen, Inc. |
Hepatitis b vaccines and uses of the same
|
US20210261647A1
(en)
|
2018-05-15 |
2021-08-26 |
Immunomic Therapeutics, Inc |
Lamp constructs comprising allergens
|
US20210361318A1
(en)
|
2018-07-02 |
2021-11-25 |
Voyager Therapeutics, Inc. |
Cannula system and use thereof
|
CN112567035A
(zh)
|
2018-07-02 |
2021-03-26 |
沃雅戈治疗公司 |
肌萎缩侧索硬化症及脊髓相关病症的治疗
|
EP3870703A1
(de)
|
2018-10-22 |
2021-09-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Rekombinantes gp120-protein mit v1-schleifendeletion
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
AU2020263900A1
(en)
|
2019-04-25 |
2021-10-14 |
Janssen Vaccines & Prevention B.V. |
Recombinant influenza antigens
|
AU2020275910A1
(en)
|
2019-05-15 |
2021-11-04 |
Janssen Vaccines & Prevention B.V. |
Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
|
WO2020229577A1
(en)
|
2019-05-15 |
2020-11-19 |
Janssen Vaccines & Prevention B.V. |
Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
|
KR20220057578A
(ko)
|
2019-09-05 |
2022-05-09 |
얀센 백신스 앤드 프리벤션 비.브이. |
인플루엔자 바이러스 백신 및 이의 용도
|
IL291852A
(en)
|
2019-10-03 |
2022-06-01 |
Janssen Vaccines & Prevention Bv |
Adenovirus vectors and their use
|
WO2021072129A2
(en)
|
2019-10-08 |
2021-04-15 |
Trustees Of Boston College |
Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
|
AU2020366515A1
(en)
|
2019-10-18 |
2022-04-21 |
Immunomic Therapeutics, Inc. |
Improved lamp constructs comprising cancer antigens
|
AU2020385683A1
(en)
|
2019-11-18 |
2022-06-30 |
Janssen Biotech, Inc. |
Vaccines based on mutant CALR and JAK2 and their uses
|
JP2023513693A
(ja)
|
2020-02-11 |
2023-04-03 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
SARS-CoV-2ワクチン
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
KR20220150353A
(ko)
|
2020-03-05 |
2022-11-10 |
네오티엑스 테라퓨틱스 엘티디. |
면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물
|
US11773391B2
(en)
|
2020-04-01 |
2023-10-03 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
|
WO2021209897A1
(en)
|
2020-04-13 |
2021-10-21 |
Janssen Biotech, Inc. |
Psma and steap1 vaccines and their uses
|
CN116096407A
(zh)
|
2020-04-29 |
2023-05-09 |
美国政府(由卫生和人类服务部的部长所代表) |
重组人偏肺病毒f蛋白及其用途
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
EP4176087A1
(de)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Verfahren zur bestimmung des ansprechens auf eine prostatakrebsbehandlung
|
WO2022009049A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
KR20230038496A
(ko)
|
2020-07-13 |
2023-03-20 |
트랜스진 |
면역 억제의 치료
|
WO2022035860A2
(en)
|
2020-08-10 |
2022-02-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Replication-competent adenovirus type 4-hiv env vaccines and their use
|
WO2022232648A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion-stabilized lassa virus glycoprotein complex and its use
|
IL308018A
(en)
|
2021-04-30 |
2023-12-01 |
Kalivir Immunotherapeutics Inc |
Oncolytic viruses for different MHC expression
|
AU2022323509A1
(en)
|
2021-08-03 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
|
CA3234811A1
(en)
|
2021-10-20 |
2023-04-27 |
Steven Goldman |
Rejuvenation treatment of age-related white matter loss
|
CA3236365A1
(en)
|
2021-11-02 |
2023-05-11 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
WO2023091696A1
(en)
|
2021-11-19 |
2023-05-25 |
Christiana Care Gene Editing Institute, Inc. |
Adenovirus delivery system for cancer treatment
|
WO2023192835A1
(en)
|
2022-03-27 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Base-covered hiv-1 envelope ectodomains and their use
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
WO2023201201A1
(en)
|
2022-04-10 |
2023-10-19 |
Immunomic Therapeutics, Inc. |
Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
EP4338727A1
(de)
|
2022-09-14 |
2024-03-20 |
Roquette Freres |
Adenovirus-formulierungen
|
WO2024091824A1
(en)
|
2022-10-26 |
2024-05-02 |
Ada Forsyth Institute, Inc. |
Differentiation and reprogramming of chondrocyte
|